Ambagon Therapeutics
0 followers
‌
Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins.
Industries
Headquarters
Employees
Links
Org chart
Scott Clarke
CEO
Scott Clarke
Collapse
Christian Ottmann
Co-Founder & Chief Technology Officer
Maarten Altelaar
Executive Director
Neil Richardson
Contract Manager
Tanja Meyer
VP & Head, Corporate Strategy & Business Development
Thomas Marty
Vice President Finance
Zhen Zhang
Sr. Director
Rao Kolluri
Director, Medicinal Chemistry
Jinxia Nancy Deng
Senior Director, Computational Chemistry
Willem van den Hout
Research Associate, Biochemistry
Rens de Vries
Scientist, Structural Biology
Ceri Zwart
Associate Scientist
Eline Sijbesma
Scientist
Galen Miley
Senior Scientist
Karolina Kaminska
Associate Scientist
Laura Demmers
Senior Scientist
Meredith Kuo
Principal Scientist
Tom van de Wijngaart
Research Associate, Structural Biology
Loes Stevers
Principal Scientist Biochemistry
Paul Hollenbach
Scientist
Donna Olivia Debets
Senior Scientist Proteomics
Michelle Pazmino
Senior Research Associate
Taggra Jackson
Sr. Research Associate
